Fig. 1From: A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary diseasePatient disposition (ITT population). aOne patient, identified as participating in another clinical study during this study, was removed from all efficacy analyses (n = 354) but retained in all safety analyses (n = 355). bOne patient receiving revefenacin 350 μg was withdrawn from the study by the investigator on D6 due to a non-treatment–emergent prolonged QTcF (>500 msc) during the screening electrocardiogram. The subject is included in both the ITT and safety populations though the prolonged QTcF adverse event is not contained in the treatment-emergent AE summaries. Abbreviations: AE: adverse event; ITT: intent to treat; QTcF: Fridericia formula for QT interval correctionBack to article page